Scarica l'app Stockscreener
3.8501
3.87%
-0.1549
Precedente Chiudi:
$4.005
Aprire:
$3.87
Volume 24 ore:
3,270
Relative Volume:
0.73
Capitalizzazione di mercato:
$144.04M
Reddito:
$786.00K
Utile/perdita netta:
$-73.94M
Rapporto P/E:
-1.9405
EPS:
-1.9841
Flusso di cassa netto:
$-60.81M
1 W Prestazione:
-10.44%
1M Prestazione:
-24.88%
6M Prestazione:
+3.79%
1 anno Prestazione:
+1.08%
Intervallo 1D:
$3.8401
$4.07
Intervallo di 1 settimana:
$3.71
$4.20
Portata 52W:
$3.36
$5.36
Molecular Partners Ag Adr Stock (MOLN) Company Profile
Nome
Molecular Partners Ag Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare MOLN vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MOLN
Molecular Partners Ag Adr
|
3.8501 | 144.04M | 786.00K | -73.94M | -60.81M | -1.9841 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Molecular Partners Ag Adr Stock (MOLN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-27 | Iniziato | H.C. Wainwright | Buy |
| 2022-08-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-08-29 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-05-25 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2022-04-27 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2021-07-13 | Iniziato | Cowen | Outperform |
| 2021-07-12 | Ripresa | SVB Leerink | Outperform |
Mostra tutto
Molecular Partners Ag Adr Borsa (MOLN) Ultime notizie
Short Interest in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Drops By 18.9% - MarketBeat
Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors - GlobeNewswire Inc.
HC Wainwright Brokers Increase Earnings Estimates for MOLN - Defense World
Damora Therapeutics, Inc. Common Stock (DMRA) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
TD Cowen reiterates Molecular Partners stock rating on radioligand platform potential By Investing.com - Investing.com South Africa
TD Cowen reiterates Molecular Partners stock rating on radioligand platform potential - Investing.com
Molecular Partners' (MOLN) Buy Rating Reiterated at HC Wainwright - MarketBeat
Molecular Partners (NASDAQ:MOLN) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Molecular Partners (NASDAQ: MOLN) outlines DARPin pipeline and cash into 2028 - Stock Titan
Will Petrobras Pull Off Q4 Earnings Beat on Strong Production? - TradingView
Molecular Partners (MOLN) to Release Quarterly Earnings on Thursday - Defense World
Molecular Partners (NASDAQ:MOLN) Stock Price Down 1.5%Should You Sell? - MarketBeat
Molecular Partners Highlights Favorable MP0712 DLL3 Radiotherapeutic Imaging, U.S. Phase I/II Ready - Yahoo Finance
Research Analysts Offer Predictions for MOLN FY2025 Earnings - Defense World
Brokers Offer Predictions for MOLN FY2025 Earnings - MarketBeat
What is HC Wainwright's Estimate for MOLN Q1 Earnings? - MarketBeat
Molecular Partners stock initiated with Buy rating at H.C. Wainwright By Investing.com - Investing.com India
Molecular Partners stock initiated with Buy rating at H.C. Wainwright - Investing.com
Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Down 17.9% in December - MarketBeat
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Update - MarketBeat
Molecular Partners (NASDAQ:MOLN) Trading Up 3.1% – Here’s What Happened - Defense World
Molecular Partners (NASDAQ:MOLN) Trading Up 3.1%Here's What Happened - MarketBeat
Molecular Partners (NASDAQ:MOLN) Price Target Cut to $3.75 by Analysts at JPMorgan Chase & Co. - Defense World
Molecular Partners (NASDAQ:MOLN) Trading Down 2.2%What's Next? - MarketBeat
EBITDA per share of Molecular Partners AG Sponsored ADR – TRADEGATE:6ML0 - TradingView
Molecular Partners (NASDAQ:MOLN) Stock Price Down 2.1% – Here’s What Happened - Defense World
Molecular Partners AG (MOLNZ.XC) Stock Price, News, Quote & History - Yahoo
Liminatus Pharma (LIMN) Short Interest Ratio and Volume 2025 - MarketBeat
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket - Benzinga
Molecular Partners to cut workforce by a quarter - Reuters
US NYSE/NASD Stock Directory - Minichart
Walmart, Deere, Applied Materials set to report earnings Thursday - Investing.com Nigeria
Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher - Yahoo Finance
J.P. Morgan Keeps Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail
Molecular Partners (MOLN) Stock Trends and Sentiment 2025 - MarketBeat
Molecular Partners (MOLN) Stock Forecast and Price Target 2026 - MarketBeat
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting By Investing.com - Investing.com South Africa
Skye Bioscience (SKYE) Short Interest & Short Float | Updated Nov 2025 - MarketBeat
symbol__ Stock Quote Price and Forecast - cnn.com
MIRA Pharmaceuticals (MIRA) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Stock Market News Today - Stock Titan
Stock Ratings and Recommendations: Understanding Analyst Ratings - MarketBeat
MAIA Biotechnology (MAIA) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Acrivon Therapeutics (ACRV) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
What is the current Price Target and Forecast for Molecular Partners AG Sponsored ADR (MOLN) - Zacks Investment Research
Senti Biosciences (SNTI) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
US stock market gainers for the last week of April 2022 - Nairametrics
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19 - novartis.com
Novartis in-licenses COVID-19 treatment ensovibep from Molecular Partners - Reuters
Molecular Partners (MOLN) 10K Form and SEC Filings 2025 - MarketBeat
Molecular Partners Ag Adr Azioni (MOLN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):